| Literature DB >> 35603877 |
Amy Whitehead1, Catharine Montgomery2, Laura Swettenham1, Nicola J Robinson1.
Abstract
In this study, we aimed to investigate the effect of Think Aloud (TA) on performance in trained and untrained participants, using functional Near Infrared Spectroscopy, during incrementally paced cycling. A mixed design was implemented with cycling expertise (10 untrained vs. 9 trained) as the between groups variable and trial stage (5 stages of increasing effort), and condition (silent vs. TA) as within groups independent variables (IVs). Dependent measures were changes in cortical oxygenation (O2Hb) in 12 areas of the prefrontal cortex (PFC) and physiological indicators of percentage heart rate maximum (%HRmax), average power output (APO), peak power output (PPO), rate of perceived exertion (RPE) and blood lactate ([La]b) over time. Trained cyclists had higher APO and significantly higher PPO from stages 2-5, in addition to a greater increase in PPO over the duration of the test (range 168W-480 W vs. 133W-313 W). There were significant main effects of stage on %HRmax, Bla and RPE (p < .001), with effect sizes (ήp2) ranging from .31 to .97. On average, HRmax%, [La]b and RPE were significantly lower after stage 2 onwards within the TA trial than the silent trial, even though similar power outputs were obtained. Thus, the TA trial elicited a better pacing strategy. There was no main effect of group on changes in O2Hb, though O2Hb did change as a function of stage in four areas of the PFC, and as a function of condition in one area. In this first study to assess the effects of TA on performance during self-paced cycling, TA did not disrupt performance outcomes at low through to high levels of physical exertion for either untrained or trained participants.Entities:
Keywords: cognition; cortical oxygenation; cycling; performance; think aloud
Mesh:
Year: 2022 PMID: 35603877 PMCID: PMC9301168 DOI: 10.1177/00315125221104769
Source DB: PubMed Journal: Percept Mot Skills ISSN: 0031-5125
Figure 3.Sensitivity Profile Created using AltasViewerGUI for Homer2 as per Aasted et al. (2015) for Optodes with Significant Main Effects: Optode 4 (3a), Optode 6 (3b) Optode 8 (3c) and Optode 9 (3d). Montreal Neurological Institute (MNI) coordinates for optodes: 1 (42 59 26); 2 (18 50 23); 3 (10 53 24); 4 (−2 46 21); 5 (−12 47 20); 6 (−24 45 16); 7 (39 57 0); 8 (20 52 0); 9 (13 74 1); 10 (−4 57 4); 11 (−20 71 1); 12 (−30 61 1).
Figure 1.All Participants (n = 19) Average Percentage Heart Rate (HR%) (grey lines) and Blood Lactate ([La]b) (black lines) Responses from post Warm Up, the five Incremental Stages and Post the Final Stage Represented as the Think AlPud (dotted line) and Silent (solid line) Trial, with Standard Deviations Displayed.
Figure 2.All Participants. (n = 19) Rate of Perceived Exertion (RPE) Responses from Post Warm Up and the Five Incremental Stage Represented as the Think Aloud (dotted line) and Silent (solid line) Trial, with Standard Deviations Displayed.
Correlational Based Signal Improvement (CBSI) Corrected Cortical Oxygenation (O2Hb) Change Across the Five Stages in Each Optode Under Silent and TA Conditions.
| Silent Stages | Think Aloud Stages | |||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | 2 | 3 | 4 | 5 | 1 | 2 | 3 | 4 | 5 | |||||||||||||
| M | SD | M | SD | M | SD | M | SD | M | SD | M | SD | M | SD | M | SD | M | SD | M | SD | |||
| Optode number | 1 | Untrained | −1.11 | 9.38 | −2.58 | 9.82 | 4.91 | 9.07 | 7.18 | 11.75 | .11 | 30.27 | −.05 | 6.28 | 1.60 | 9.37 | 1.14 | 15.26 | 3.45 | 9.54 | 1.45 | 16.84 |
| Trained | −.91 | 4.63 | .02 | 7.41 | 1.71 | 6.98 | 5.03 | 5.95 | 3.10 | 9.44 | 2.61 | 10.81 | 4.25 | 7.85 | 2.50 | 1.01 | 5.34 | 11.66 | 7.15 | 10.66 | ||
| 2 | Untrained | 5.43 | 6.77 | −5.10 | 20.41 | 2.10 | 12.21 | 5.91 | 8.39 | 1.20 | 12.06 | 1.52 | 2.26 | .55 | 5.49 | 2.41 | 5.36 | 1.33 | 7.83 | 1.15 | 13.06 | |
| Trained | .32 | 4.20 | 3.51 | 6.81 | 5.55 | 9.30 | 6.87 | 10.11 | 8.69 | 9.07 | −.04 | 5.97 | .57 | 5.57 | .68 | 4.74 | 1.60 | 10.37 | 3.08 | 7.28 | ||
| 3 | Untrained | 6.74 | 10.23 | 5.15 | 11.43 | 2.91 | 10.61 | 6.21 | 7.54 | 5.21 | 9.78 | .80 | 1.26 | −89 | 6.02 | .26 | 4.69 | −.40 | 6.66 | 1.04 | 8.02 | |
| Trained | 5.29 | 18.00 | 7.04 | 19.67 | 9.72 | .45 | 7.03 | 14.54 | 8.01 | 15.33 | 3.06 | 6.47 | 2.20 | 7.09 | 3.26 | 5.70 | 4.90 | 7.87 | 3.46 | 8.92 | ||
| 4 | Untrained | −2.72 | 5.11 | −3.96 | 4.89 | −9.33 | 5.95 | −9.93 | 8.93 | −9.66 | 10.48 | 1.09 | 5.07 | 1.01 | 5.45 | .51 | 6.17 | −1.53 | 7.01 | −3.37 | 6.23 | |
| Trained | −.80 | 2.31 | −.52 | 2.80 | −3.37 | 3.63 | −5.25 | 4.55 | −6.88 | 6.42 | −.01 | 5.02 | −.53 | 6.79 | 02 | 9.92 | −3.95 | 8.03 | −5.20 | 5.97 | ||
| 5 | Untrained | 1.16 | 11.60 | 4.70 | 21.14 | 6.55 | 26.83 | 5.91 | 33.81 | 8.86 | 27.39 | 5.52 | 17.59 | 10.08 | 22.63 | 11.78 | 27.93 | 11.20 | 26.74 | 11.93 | 24.75 | |
| Trained | .53 | 6.15 | 2.68 | 4.88 | .51 | 6.68 | .54 | 7.88 | 3.49 | 7.27 | 6.90 | 11.36 | 9.88 | 12.28 | 7.26 | 10.36 | 7.98 | 13.77 | 9.17 | 12.54 | ||
| 6 | Untrained | −2.48 | 6.11 | −5.17 | 6.93 | −6.23 | 9.64 | 9.93 | 8.93 | −15.41 | 12.66 | −3.75 | 7.10 | −4.95 | 9.25 | −5.90 | 9.71 | −8.18 | 10.42 | −9.45 | 10.35 | |
| Trained | −.90 | 3.72 | −1.38 | 2.69 | −3.19 | 4.14 | −5.25 | 4.55 | −6.23 | 6.57 | −4.79 | 4.30 | −5.00 | 5.33 | −4.84 | 7.11 | −5.49 | 3.86 | −7.44 | 7.35 | ||
| 7 | Untrained | 1.19 | 4.66 | 2.17 | 4.60 | 2.84 | 9.48 | 5.39 | 14.96 | 7.75 | 24.23 | −1.59 | 4.99 | −2.86 | 9.65 | .64 | 6.56 | −1.36 | 9.83 | 3.23 | 5.32 | |
| Trained | .69 | 8.09 | 4.20 | 6.95 | 7.03 | 12.63 | 5.65 | 12.45 | 5.07 | 14.58 | 3.82 | 5.99 | 3.55 | 4.83 | 3.64 | 4.56 | 1.44 | 4.69 | 1.68 | 6.98 | ||
| 8 | Untrained | −5.26 | 6.01 | −7.99 | 6.52 | −10.51 | 9.13 | −9.99 | 8.97 | −8.79 | 9.65 | −.17 | 4.00 | .42 | 3.60 | −1.39 | 4.78 | −4.31 | 8.48 | −7.35 | 7.83 | |
| Trained | −.20 | 5.12 | .75 | 6.37 | −4.20 | 6.84 | −5.90 | 7.64 | −8.29 | 8.46 | .76 | 3.16 | −3.00 | 3.36 | −4.05 | 3.60 | −7.03 | 5.81 | −9.81 | 8.16 | ||
| 9 | Untrained | 2.43 | 2.13 | 4.37 | 3.12 | 6.00 | 2.60 | 8.73 | 2.10 | 14.28 | 8.78 | 1.79 | 2.58 | 2.60 | 1.95 | 3.49 | 2.79 | 4.27 | 3.24 | 5.07 | 6.54 | |
| Trained | .52 | 1.93 | 2.09 | 2.25 | 2.13 | 3.19 | 4.09 | 3.32 | 7.64 | 2.95 | 1.26 | 3.29 | 2.36 | 5.29 | 3.05 | 5.17 | 5.52 | 6.10 | 8.28 | 6.25 | ||
| 10 | Untrained | −1.72 | 3.94 | −5.65 | 6.44 | −5.36 | 9.35 | −.49 | 26.81 | −5.89 | 27.41 | −.8/0 | 8.05 | .95 | 11.43 | .15 | 15.73 | −.53 | 11.27 | 4.97 | 22.73 | |
| Trained | −.05 | 3.54 | −1.67 | 2.49 | −2.28 | 3.11 | −9.98 | 16.15 | −8.72 | 5.28 | −1.42 | 12.36 | −.70 | 19.67 | −2.51 | 15.73 | −8.85 | 13.35 | −12.16 | 10.60 | ||
| 11 | Untrained | 4.45 | 9.98 | −4.87 | 14.57 | −7.44 | 24.96 | −3.76 | 24.79 | 2.99 | 31.59 | 10.77 | 27.23 | 5.39 | 20.02 | 9.81 | 19.09 | 9.23 | 17.58 | 8.70 | 13.33 | |
| Trained | −4.88 | 14.57 | 1.58 | 6.61 | −1.93 | 19.88 | 4.94 | 11.42 | −5.12 | 15.48 | 7.85 | 19.19 | 4.40 | 22.04 | 7.92 | 19.64 | 3.05 | 15.74 | 2.51 | 19.91 | ||
| 12 | Untrained | −.001 | .004 | −.001 | .003 | −.001 | .003 | −.001 | .031 | −.007 | .003 | .001 | .001 | .003 | .005 | .001 | .003 | .006 | .001 | .001 | .001 | |
| Trained | .001 | .001 | .011 | .001 | .001 | .001 | .001 | .001 | .001 | .001 | .001 | .001 | .001 | .001 | .001 | .001 | .001 | .001 | .001 | .001 | ||
Mixed ANOVA Statistics and Significance Levels for Optodes with significant Main Effects.
| Conditio | Condition*Group (1.17) | Stage | Stage*Group | Condition*Stage | Condition*Stage*Group | Group (1.17) | |||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| F | p | F | p | df | F | p | Ƞp2 | Significant Pairwise Comparisons | df | F | p | df | F | p | Ƞp2 | df | F | p | F | p | |
| Optode 4 | 4.64 | .05 | 1.94 | .18 | (2.14.31.18) | 11.37 | .001 | .40 | Stage 1 and 4 – | (2.14.31.18) | .41 | .68 | (1.83.31.18) | 1.68 | .20 | — | (1.83.31.18) | .34 | .70 | .69 | .42 |
| Left | |||||||||||||||||||||
| Optode 6 | .03 | .86 | 70 | .41 | (2.15.42.34) | 8.02 | .001 | .32 | Stage 1 and 4 – | (2.1542.34) | .1.17 | .33 | (2.49.42.34) | 1.80 | .17 | — | (2.49.42.34) | .55 | .62 | 2.12 | .16 |
| Left | |||||||||||||||||||||
| Optode 8 | 1.78 | .20 | 3.68 | .07 | (2.79.43.07) | 13.62 | .001 | .45 | Stage 1 and 3 – | (2.79.43.07) | .74 | .53 | (2.53.43.07) | 1.83 | .16 | — | (2.53.43.07) | 1.41 | .25 | .42 | .53 |
| Right | |||||||||||||||||||||
| Optode 9 | 2.36 | .14 | 5.65 | .03 | (1.63.28.55) | 25.07 | .0001 | .60 | Stage 1 and 2 – | (4.63.28.55) | .11 | .85 | (1.68.28.55) | 3.35 | .06 | — | (1.68.28.55) | 3.54 | .05 | 2.27 | .14 |
| Right | |||||||||||||||||||||